// App-Quantinova.ai

608 : Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).

Researchers

Presenter

  • Carmine De Angelis

Principal Investigators

  • Chandandeep Nagi

  • Cliff Hoyt

  • Liu Linying

  • Kristin Roman

  • Chichung Wang

  • Yi Zheng

  • Tao Wang

  • Rena Mao

  • Susan G. Hilsenbeck

  • Carolina Gutierrez

  • Antonio C. Wolff

  • C. Kent Osborne

  • Mothaffar F. Rimawi

  • Rachel Schiff

Medical Centers

  • Baylor College of Medicine, Houston, TX

  • PerkinElmer, Inc., Hopkinton, MA

  • Smith Breast Center At BCM, Houston, TX

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • United States

Companies

  • PerkinElmer, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • B-lymphocyte antigen CD20

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Human epidermal growth factor receptor 2

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Trastuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved